XORTX Elects to Delist from TSX Venture Exchange

XORTX Therapeutics voluntarily delists its common shares from the TSX Venture Exchange. The company determined the dual listing did not justify associated costs and administrative requirements. Canadian shareholders will maintain full trading access on Nasdaq. No shareholder action is required.